Home
Loading

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

Get in touch

  • Contact

  • Request a demo

  • Request data updates

  • Add a company

Research

  • Companies

  • Investors

  • People

aVenture

  • Sitemap

  • Feature requests

Member

Backed by

© aVenture Investment Company, 2026. All rights reserved.

San Francisco, CA, USA

Privacy Policy

aVenture Investment Company ("aVenture") is an independent research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals. It is not a registered investment adviser, broker-dealer, or investment advisor and does not provide investment advice or recommendations. The data provided by aVenture does not constitute recommendations or advice, whether by methodology, analysis, AI-generated content, or a statement written by a staff member of aVenture.

aVenture is not affiliated with any of the people, companies, organizations, government agencies, regulatory bodies, or investment funds we provide coverage for on this site unless explicitly stated otherwise. Users assume full responsibility for decisions made based on information obtained from this platform. Links to external websites do not imply endorsement or affiliation with aVenture. Any links that provide the ability to invest in a primary or secondary transaction in a company are for convenience only and do not constitute solicitations or offers to buy or sell an investment. Investors should exercise heightened precaution and due diligence when investing in private companies, especially those not independently audited.

While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision. To the fullest extent permitted by law, aVenture shall not be liable for any direct, indirect, incidental, consequential, or financial damages arising from use of this site, whether by consumers of its contents directly or by persons or organizations covered by our research, even if we are advised of the possibility. Our best-efforts processes and correction request forms do not create a warranty or duty of care.

Profiles on this platform may include content generated in part by large language models (LLMs, artificial intelligence) that aggregate publicly available sources (e.g., SEC EDGAR, public filings, press releases). Source attribution is provided where known; always verify statements and claims here against original sources before relying on any data. Content on our site may contain inaccuracies, omissions, or what are commonly called 'hallucinations' if generated in part or in full by AI / LLMs. The risk can also exist even when content is written by a human, as internal and third-party sources may also have inaccuracies for the same or different reasons. While we randomly audit a proportion of content, this is not exhaustive.

We recommend that an independent auditor be hired to verify the accuracy of the information before relying on it for any sensitive decisions. By accessing this platform, you agree not to rely solely on any information generated by AI, aggregated, or sourced or written otherwise on this site, for investment, financial, or other decisions. aVenture assumes no responsibility for inaccuracies, omissions, or hallucinations. You must independently verify all data from primary sources. Use of this platform constitutes your waiver of claims for reliance-based damages, including negligent misrepresentation. To report an error, request a correction, or dispute information about a company or individual, contact us via our request data updates form.

Loading
Loading
Home
News
Luminoah’s quest to reinvent tube feeding attracts new funding

From TechCrunch

By Devin Coldewey

June 15, 2023

Luminoah’s quest to reinvent tube feeding attracts new funding

When someone is very ill or has had surgery that interrupts ordinary ways of eating and drinking, tube feeding is life-saving necessity — but it’s cumbersome and uncomfortable to use. Luminoah aims to change this with a reinvented tube feeding device that’s more portable, discreet, and easy to use, and it has raised $6 million to bring its design to market.

Ordinary tube feeding setups are generally found in hospitals, and are wheeled around like IVs and other gear. That makes sense in a controlled, medical environment, but what if you or your loved one has to do it for months in and out of the hospital? Wheeling a tube feeding mechanism around a home or school is much more difficult and probably quite unpleasant.

Luminoah founder Neal Piper was confronted with this issue when his toddler required tube feeding during treatment for cancer (he is fine now, by the way).

“During his treatment, Noah was tethered to a pole-mounted tube feeding system for up to 15 hours per day. This outdated technology limited his mobility, reduced his quality of life, and presented numerous well-documented health risks,” explained Piper in a news release.

This is often the case with medical devices: the old way works fine but hasn’t been updated in years or decades due to the cost of development and complexity of entering the medical device market. Piper and Luminoah seem to have struck a chord with investors, however, leading to this $6 million A round led by Fry’s Path Capital, with participation from Sands Capital, CAV Angels, Virginia Venture Partners, and 757 Angels.

“Our system has made substantial improvements to the size of the hardware allowing our engineering team to redefine the traditional approach to IV-pole bound infusion pumps,” Piper told TechCrunch. “Users will enjoy a modern UI/UX that affords them discretion while feeding paired with a device that allows them to go about their day unencumbered.” (As the design of the device is not final, the company is not yet publishing images of it.)

Being a connected device, it would also collect metrics for medical providers to check akin to what they would learn if the patient was in a hospital room with a traditional pole-mounted system.

The plan is to make the device reimbursable by insurance, though it’s a long road to get there. The funding should at least take it to prototype stage.

“With our newly raised round, we will rapidly advance development and prepare for the commercialization of our system. We are excited to grow our team further as we continue to march towards these exciting milestones,” he said.

Quality of life is a genuinely important factor in recovery, especially among young people who have yet to develop the kind of coping mechanisms adults use to get through tough times like cancer treatment. Reducing the discomfort and increasing the dignity of live-preserving treatments isn’t just a “nice to have” — it will likely contribute to better patient outcomes.

Luminoah’s quest to reinvent tube feeding attracts new funding by Devin Coldewey originally published on TechCrunch

Most Recent

Colossal Biosciences reportedly in talks to raise new capital at $20B–$30B valuation

Colossal Biosciences reportedly in talks to raise new capital at $20B–$30B valuation

The de-extinction startup is looking to double or triple its previous valuation, according to the report.

Jul 20, 2026

Natural raises $30M to reinvent payments for AI agents — and take on Stripe

Natural raises $30M to reinvent payments for AI agents — and take on Stripe

The one-year-old startup aims to reinvent financial architecture for autonomous AI transactions.

Jul 20, 2026

Inference startup Infinity raises $15M from Touring Capital, OpenAI and Anthropic researchers

Inference startup Infinity raises $15M from Touring Capital, OpenAI and Anthropic researchers

AI infrastructure company Infinity announced Monday a $15 million raise at a $100 million valuation from investors including Touring Capital, Principal VC, and researchers from companies such as OpenAI and Anthropic.

Jul 20, 2026

StrictlyVC returns to New York City September 10 to celebrate a huge year for the city’s startup community

StrictlyVC returns to New York City September 10 to celebrate a huge year for the city’s startup community

For the first time since 2024, StrictlyVC is coming back to New York City — and we're bringing the kind of access you’d expect from an under-wraps event to the whole startup, VC, and dealmaking community.

Jul 20, 2026

Similar Posts

Sam Altman’s World unveils a mobile verification device

Sam Altman’s World unveils a mobile verification device

Tools for Humanity, the startup behind the World human verification project, unveiled a mobile verification device and expanded to the US.

Apr 30, 2025

Meet Posha, a countertop robot that cooks your meals for you

Meet Posha, a countertop robot that cooks your meals for you

Posha's $1,750 device of the same name sold out its first batch and has seen strong word-of-mouth growth since.

May 6, 2025

Blackrock Neurotech's MoveAgain Brain-Computer Interface System Receives FDA Breakthrough Device Designation

Blackrock Neurotech's MoveAgain Brain-Computer Interface System Receives FDA Breakthrough Device Designation

FDA grants Breakthrough Device designation to Blackrock Neurotech's MoveAgain BCI system, expediting review for the implant that lets immobile patients control cursors, wheelchairs, and prosthetics by thought.

Nov 15, 2021

Hippocratic is building a large language model for healthcare

Hippocratic is building a large language model for healthcare

AI, specifically generative AI, has the potential to transform healthcare. At least, that sales pitch from Hippocratic Health, which emerged from stealth today with a whopping $50 million in seed financing behind it and a valuation in the “triple digit millions.” The tranche, co-led by General Catalyst and Andreessen Horowitz, is a big vote of […]

May 16, 2023

Most Recent

Colossal Biosciences reportedly in talks to raise new capital at $20B–$30B valuation

Colossal Biosciences reportedly in talks to raise new capital at $20B–$30B valuation

The de-extinction startup is looking to double or triple its previous valuation, according to the report.

Jul 20, 2026

Natural raises $30M to reinvent payments for AI agents — and take on Stripe

Natural raises $30M to reinvent payments for AI agents — and take on Stripe

The one-year-old startup aims to reinvent financial architecture for autonomous AI transactions.

Jul 20, 2026

Inference startup Infinity raises $15M from Touring Capital, OpenAI and Anthropic researchers

Inference startup Infinity raises $15M from Touring Capital, OpenAI and Anthropic researchers

AI infrastructure company Infinity announced Monday a $15 million raise at a $100 million valuation from investors including Touring Capital, Principal VC, and researchers from companies such as OpenAI and Anthropic.

Jul 20, 2026

StrictlyVC returns to New York City September 10 to celebrate a huge year for the city’s startup community

StrictlyVC returns to New York City September 10 to celebrate a huge year for the city’s startup community

For the first time since 2024, StrictlyVC is coming back to New York City — and we're bringing the kind of access you’d expect from an under-wraps event to the whole startup, VC, and dealmaking community.

Jul 20, 2026

Similar Posts

Sam Altman’s World unveils a mobile verification device

Sam Altman’s World unveils a mobile verification device

Tools for Humanity, the startup behind the World human verification project, unveiled a mobile verification device and expanded to the US.

Apr 30, 2025

Meet Posha, a countertop robot that cooks your meals for you

Meet Posha, a countertop robot that cooks your meals for you

Posha's $1,750 device of the same name sold out its first batch and has seen strong word-of-mouth growth since.

May 6, 2025

Blackrock Neurotech's MoveAgain Brain-Computer Interface System Receives FDA Breakthrough Device Designation

Blackrock Neurotech's MoveAgain Brain-Computer Interface System Receives FDA Breakthrough Device Designation

FDA grants Breakthrough Device designation to Blackrock Neurotech's MoveAgain BCI system, expediting review for the implant that lets immobile patients control cursors, wheelchairs, and prosthetics by thought.

Nov 15, 2021

Hippocratic is building a large language model for healthcare

Hippocratic is building a large language model for healthcare

AI, specifically generative AI, has the potential to transform healthcare. At least, that sales pitch from Hippocratic Health, which emerged from stealth today with a whopping $50 million in seed financing behind it and a valuation in the “triple digit millions.” The tranche, co-led by General Catalyst and Andreessen Horowitz, is a big vote of […]

May 16, 2023